Patents by Inventor Keith Gorden

Keith Gorden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICRENVIRONMENT
    Publication number: 20250114392
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: May 20, 2024
    Publication date: April 10, 2025
    Applicant: HiberCell, Inc.
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20250114391
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: May 17, 2024
    Publication date: April 10, 2025
    Applicant: HiberCell, Inc.
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
    Publication number: 20250009782
    Abstract: This disclosure relates to soluble ?-glucan immunotherapies that affect the tumor microenvironment. The soluble ?-glucan immunotherapies promote an immunostimulatory environment, which enhances the effectiveness of the combination of anti-angiogenics and checkpoint inhibitors.
    Type: Application
    Filed: September 23, 2024
    Publication date: January 9, 2025
    Inventors: Nandita Bose, Keith Gorden, Ross Fulton, Steven Leonardo, Jeremy Graff
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20240350528
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: October 24, 2023
    Publication date: October 24, 2024
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
    Publication number: 20230172967
    Abstract: This disclosure relates to soluble ?-glucan immunotherapies that affect the tumor microenvironment. The soluble ?-glucan immunotherapies promote an immunostimulatory environment, which enhances the effectiveness of the combination of anti-angiogenics and checkpoint inhibitors.
    Type: Application
    Filed: August 12, 2022
    Publication date: June 8, 2023
    Inventors: Nandita Bose, Keith Gorden, Ross Fulton, Steven Leonardo, Jeremy Graff
  • BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
    Publication number: 20220117998
    Abstract: This disclosure relates to soluble ?-glucan immunotherapies that affect the tumor microenvironment. The soluble ?-glucan immunotherapies promote an immunostimulatory environment, which enhances the effectiveness of the combination of anti-angiogenics and checkpoint inhibitors.
    Type: Application
    Filed: December 30, 2021
    Publication date: April 21, 2022
    Inventors: Nandita Bose, Keith Gorden, Ross Fulton, Steven Leonardo, Jeremy Graff
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20220047620
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: March 29, 2021
    Publication date: February 17, 2022
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20210283169
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: March 29, 2021
    Publication date: September 16, 2021
    Inventors: Nandita Bose, Keith Gorden, Anissa SH. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20190060350
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20190060351
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 28, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON, Ross FULTON
  • BETA-GLUCAN IMMUNOTHERAPIES AFFECTING THE IMMUNE MICROENVIRONMENT
    Publication number: 20190022129
    Abstract: This disclosure relates to soluble ?-glucan immunotherapies that affect the tumor microenvironment. The soluble ?-glucan immunotherapies promote an immunostimulatory environment, which enhances the effectiveness of the combination of anti-angiogenics and checkpoint inhibitors.
    Type: Application
    Filed: January 9, 2017
    Publication date: January 24, 2019
    Inventors: Nandita BOSE, Keith GORDEN, Ross FULTON, Steve LEONARDO, Jeremy GRAFF
  • ?-glucan methods and compositions that affect the tumor microenvironment
    Patent number: 10111900
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa Sh. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
    Patent number: 10111901
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 30, 2018
    Assignee: BIOTHERA, INC.
    Inventors: Nandita Bose, Keith Gorden, Anissa S H. Chan, Steven Leonardo, Jeremy Graff, Xiaohong Qiu, Takashi Kangas, Kathryn A. Fraser, Adria Bykowski Jonas, Nadine Ottoson, Ross Fulton
  • BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT
    Publication number: 20170100425
    Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON
  • BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT
    Publication number: 20170100424
    Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Nandita BOSE, Keith GORDEN, Anissa SH. CHAN, Steven LEONARDO, Jeremy GRAFF, Xiaohong QIU, Takashi KANGAS, Kathryn A. FRASER, Adria BYKOWSKI JONAS, Nadine OTTOSON
  • Methods and compositions related to IRM compounds and toll-like receptor pathways
    Publication number: 20050245564
    Abstract: Methods for identifying a compound that activates a TLR-mediated cellular signaling pathway is disclosed. The method includes (a) exposing a TLR-positive cell culture to a test compound and measuring a TLR-mediated cellular response; (b) exposing a TLR-negative cell culture to a test compound and measuring a TLR-mediated cellular response; and (c) identifying the test compound as an IRM if the cellular response in the TLR-positive cell culture is greater than the cellular response of the TLR-negative cell culture. Methods of eliciting a TLR-mediated cellular response are also disclosed. Such methods include administration of an IRM compound to an IRM-responsive cell so that the IRM compound affects at least one TLR-mediate cellular signaling pathway.
    Type: Application
    Filed: June 15, 2005
    Publication date: November 3, 2005
    Inventors: Keith Gorden, Xiaohong Qiu, Mark Tomai, John Vasilakos